Mesoblast Secures US FDA Orphan Drug Designation for Cell Therapy; Shares Jump 7%

Mesoblast 获得美国食品药品管理局细胞疗法孤儿药认证；股价上涨 7%

MT Newswires · 02/14 21:15

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Mesoblast Secures US FDA Orphan Drug Designation for Cell Therapy; Shares Jump 7%

Mesoblast Secures US FDA Orphan Drug Designation for Cell Therapy; Shares Jump 7%

风险及免责提示

声明